Report date: Apr 23, 2024
Conflict count: 350216
Publisher: Canadian Journal of Health Technologies, CADTH
Title count: 1
Conflict count: 15


==========================================================

Created: 2021-12-20 23:06:25.0
ConfID: 6402042
CauseID: 1515820561
OtherID: 1515668588
JT: Canadian Journal of Health Technologies
MD: Reimbursement Team, 1 ,12,null,2021,Pembrolizumab (Keytruda)
DOI: 10.51731/cjht.2021.225(Journal) (6402042-N )
DOI: 10.51731/cjht.2021.228(Journal)
==========================================================

Created: 2022-02-25 00:42:57.0
ConfID: 6439832
CauseID: 1521965815
OtherID: 1520610542
JT: Canadian Journal of Health Technologies
MD: Reimbursement Team, 2 ,2,null,2022,Estradiol (Imvexxy)
DOI: 10.51731/cjht.2022.254(Journal) (6439832-N )
DOI: 10.51731/cjht.2022.271(Journal)
==========================================================

Created: 2022-03-30 01:27:01.0
ConfID: 6458298
CauseID: 1525135236
OtherID: 1524618441
JT: Canadian Journal of Health Technologies
MD: Reimbursement Team, 2 ,3,null,2022,Nivolumab (Opdivo)
DOI: 10.51731/cjht.2022.287(Journal) (6458298-N )
DOI: 10.51731/cjht.2022.296(Journal)
==========================================================

Created: 2022-07-19 03:03:53.0
ConfID: 6568305
CauseID: 1536020216
OtherID: 1535621683
JT: Canadian Journal of Health Technologies
MD: CADTH, 2 ,7,null,2022,Selpercatinib (Retevmo)
DOI: 10.51731/cjht.2022.391(Journal) (6568305-N )
DOI: 10.51731/cjht.2022.395(Journal)
==========================================================

Created: 2022-09-21 03:48:34.0
ConfID: 6596430
CauseID: 1542299736
OtherID: 1542299732
JT: Canadian Journal of Health Technologies
MD: CADTH, 2 ,9,null,2022,Atezolizumab (Tecentriq)
DOI: 10.51731/cjht.2022.450(Journal) (6596430-N )
DOI: 10.51731/cjht.2022.449(Journal)
==========================================================

Created: 2022-10-22 04:08:50.0
ConfID: 6659326
CauseID: 1545613503
OtherID: 1543654504
JT: Canadian Journal of Health Technologies
MD: CADTH, 2 ,10,null,2022,Ruxolitinib (Jakavi)
DOI: 10.51731/cjht.2022.460(Journal) (6659326-N )
DOI: 10.51731/cjht.2022.478(Journal)
==========================================================

Created: 2022-12-16 04:41:39.0
ConfID: 6688575
CauseID: 1554530850
OtherID: 1553776881
JT: Canadian Journal of Health Technologies
MD: CADTH, 2 ,12,null,2022,Atezolizumab (Tecentriq)
DOI: 10.51731/cjht.2022.523(Journal) (6688575-N )
DOI: 10.51731/cjht.2022.526(Journal)
==========================================================

Created: 2022-12-20 04:42:58.0
ConfID: 6689660
CauseID: 1554969774
OtherID: 1554831792
JT: Canadian Journal of Health Technologies
MD: CADTH, 2 ,12,null,2022,Pembrolizumab (Keytruda)
DOI: 10.51731/cjht.2022.525(Journal) (6689660-N )
DOI: 10.51731/cjht.2022.527(Journal)
==========================================================

Created: 2023-01-25 05:03:44.0
ConfID: 6713500
CauseID: 1559187978
OtherID: 1559072533
JT: Canadian Journal of Health Technologies
MD: CADTH, 3 ,1,null,2023,Pembrolizumab (Keytruda)
DOI: 10.51731/cjht.2023.541(Journal) (6713500-N )
DOI: 10.51731/cjht.2023.550(Journal)
==========================================================

Created: 2023-02-09 05:11:48.0
ConfID: 6718251
CauseID: 1560939856
OtherID: 1560259560
JT: Canadian Journal of Health Technologies
MD: CADTH, 3 ,2,null,2023,Cariprazine (Vraylar)
DOI: 10.51731/cjht.2023.558(Journal) (6718251-N )
DOI: 10.51731/cjht.2023.570(Journal)
==========================================================

Created: 2023-02-09 05:12:11.0
ConfID: 6718252
CauseID: 1560939880
OtherID: 1560817514
JT: Canadian Journal of Health Technologies
MD: CADTH, 3 ,2,null,2023,Dupilumab (Dupixent)
DOI: 10.51731/cjht.2023.559(Journal) (6718252-N )
DOI: 10.51731/cjht.2023.567(Journal)
==========================================================

Created: 2023-02-23 05:19:22.0
ConfID: 6720720
CauseID: 1562516932
OtherID: 1561048185
JT: Canadian Journal of Health Technologies
MD: CADTH, 3 ,2,null,2023,Pembrolizumab (Keytruda)
DOI: 10.51731/cjht.2023.561(Journal) (6720720-N )
DOI: 10.51731/cjht.2023.579(Journal)
==========================================================

Created: 2023-03-22 05:05:31.0
ConfID: 6761252
CauseID: 1565892309
OtherID: 1565247070
JT: Canadian Journal of Health Technologies
MD: CADTH, 3 ,3,null,2023,Pembrolizumab (Keytruda)
DOI: 10.51731/cjht.2022.596(Journal) (6761252-N )
DOI: 10.51731/cjht.2023.603(Journal)
==========================================================

Created: 2023-04-19 05:14:46.0
ConfID: 6792246
CauseID: 1570166172
OtherID: 1570010709
JT: Canadian Journal of Health Technologies
MD: CADTH, 3 ,4,null,2023,Dupilumab (Dupixent)
DOI: 10.51731/cjht.2023.618(Journal) (6792246-N )
DOI: 10.51731/cjht.2023.622(Journal)
==========================================================

Created: 2023-09-09 06:03:10.0
ConfID: 6929546
CauseID: 1588697955
OtherID: 1588193421
JT: Canadian Journal of Health Technologies
MD: CADTH, 3 ,8,null,2023,Dapagliflozin
DOI: 10.51731/cjht.2023.718(Journal) (6929546-N )
DOI: 10.51731/cjht.2023.732(Journal)